Rheumatoid arthritis (RA) is associated with an excess cardiovascular morbidity and mortality, related to systemic inflammation with endothelial dysfunction (ED) and impaired flow-mediated vasodilation (FMD). We assessed the FMD response to anti-TNF-a treatments in 28 RA patients, aged 49.8±15.3 years: an unpaired FMD was found in 66.7% of our cases and was restored after 6 weeks of anti-TNF-a treatment (13.5±5.3% vs 4.6±4.1 %, p < 0.05). Twenty-five percent of the infliximab patients demonstrated a long term response, compared with 60% of etanercept and 100% of adalimumab patients, after 2 years (p<O.OI). Infections (3 cases), myocardial ischemia (I case) or loss of response (4 cases) were associated with a worsened FMD, restored by shifting to adalimumab. The present study confirms that ED is an RA systemic disease marker, responsive to anti-TNF-a treatment and sensitive to clinical events or to a loss of response, underlying the biological coherence between synovial and endothelial inflammation.
Rheumatoid arthritis (RA) is a chronic inflammatory disease, with a reduced life expectancy associated with an excessive cardiovascular morbidity and mortality, predominantly due to clinical manifestations of accelerated atherosclerosis, such as coronary artery disease, chronic heart failure and cerebrovascular disease (1-2). Systemic endothelial involvement is characterized by endothelial dysfunction (ED), which in RA seems only slightly related to traditional cardiac risk factors, but strongly related with systemic inflammatory markers (3) . The vascular changes in RA are related to early onset and high activity of rheumatoid disease and to some specific RA characteristics, as early inflammatory polyarthritis, high levels of rheumatoid factor and to the effects of the pro-inflammatory cytokines (3) (4) (5) (6) .
Overt cardiovascular involvement manifests itself with a high occurrence of symptomatic myocardial ischemia or infarction, which is preceded by a long subclinical period characterized by ED and subsequent irreversible endothelial damage, referred to the basic mechanisms of atherosclerosis, which is regarded as a low-grade inflammatory disease (7) (8) (9) .
ED includes changes in the anti-inflammatory and anticoagulant properties of the endothelial cells, with an overexpression of adhesion molecules and inflammatory cell recruitment and an impairment of the arterial vasoregulatory responses (7) . This results in a poor endothelial-dependent vasodilation, sometimes associated with abnormal vasoconstrictive responses, which may be measured in a non-invasive manner (7) (8) .
There are many factors which seem to playa role in this abnormal arterial tone regulation but the main one appears to be TNF-a. The ED ofRA is currently thought to be due to the interaction among traditional risk factors with RA pro-inflammatory cytokines, such as tumor necrosis factor-a (TNF-a) and interleukin-Iji. This leads to functional endothelial changes that are thought to precede the development of the structural changes of atherosclerosis, with irreversible vascular damage (6, 8, (10) (11) .
Recently, anti-TNF-a treatment has been demonstrated to provide clinical benefits by reducing RA activity and improving the inflammatory process, by counteracting the unfavourable systemic effects of this cytokine (12) (13) (14) . There is increasing evidence that biological TNFa antagonists are able to counteract rheumatoid ED, currently considered to be a shared pathway for a broad spectrum of noxious agents ranging from classic risk factors to other newly recognized ones, such as inflammatory cytokines (7, 11) .
The present study aims to evaluate the effects of anti-TNF-a treatments on ED in RA patients nonresponders to usual DMARDs (12) (13) , by following the ED changes in patients who experienced a persistent response compared to subjects in whom the biological anti-TNF-a drugs were withdrawn because of significant adverse effects or loss of response. We also evaluated the pattern of endothelial response in subjects after switching from one anti-TNFa agent to another available anti-TNFa antagonist, in order to assess the FMD responses to each anti-TNF a treatment.
MATERIALS AND METHODS
We evaluated 24 patients (of whom 22 were female) aged 49.8 ± 15.3 years (range 18-75 yrs), suffering from RA for at least 4 months (mean 105 ± 96 months, range 18-268 months), fulfilling the ACR criteria with a Disease Activity Score (DAS):::: 3.7 despite standard antirheumatic treatment with at least two disease-modifying anti-rheumatic drugs (DMARDs) for >4 months (15) . All patients received low-dose corticosteroids (::::10 mg/day); 12 patients were treated with methotrexate with folate supplementation; seven patients were affected by mild hypertension and five were hypercholesterolemic, all of them treated with statins. One patient was a current smoker. All patients were participants of the observational study "Antares" of the Italian Health Ministry and provided written informed consent.
The evaluation of patients included complete history, physical examination, routine laboratory tests with determination of C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), glucose, total cholesterol, HDL and LDL cholesterol, rheumatoid factor, antinuclear antibodies, and anti-dsDNA antibodies; the patients also underwent tine test, chest X-ray and Doppler echocardiogram at the beginning of the study.
Patients were excluded in the presence of conditions which contraindicated anti-TNF-a treatment such as pregnancy, infections, malignancies, heart, renal or liver failure; the occurrence of these conditions or of a loss of response to the treatment, were stated as criteria to stop the current anti-TNF-a treatment, eventually shifting the patient to another biological drug, when appropriate.
Anti-TNFa treatment was added to the previous treatment, which remained unchanged throughout the entire course of the study.
Eight patients, all taking methotrexate, were treated by infliximab (Remicade®: Schering-Plough, Milan, Italy; Centocor RY., Leiden, the Netherlands), administered intravenously at the dosage of 3 mglkg over 2 h; the treatment with infliximab was repeated after 2 weeks, after a further 4 weeks and subsequently every 8 weeks. Ten patients, four of them taking methotrexate, were treated with etanercept (Enbrel®: Wyeth Lederle, Aprilia, Italy; Wyeth Europe, Berkshire, United Kingdom), self-administered by subcutaneous injection at the dosage of 25 mg twice a week. Ten patients, including 4 initially receiving infliximab and taking methotrexate, were treated with adalimumab (Humira®: Abbott, Latina, Italy; Laboratories, Abbott Park, IL), self-administered by subcutaneous injection at the dosage of 40 mg every 2 weeks. The effects of the treatment on RA were assessed by clinical and laboratory evaluation, comprehensive of the Disease Activity Score 28 (DAS28) and the Health Assessment Questionnaire Disability Index (HAQ) scores. Routine reassessment included physical examination, standard laboratory measures, other diagnostic tools, as indicated, and reports ofadverse events experienced throughout the treatment by each patient. The control group consisted of 15 healthy female volunteers aged 53 ± 9 yrs (p =ns).
Endothelial function study
Endothelial function was studied using the ultrasound method according to current guidelines (16) . Brachial artery reactivity was assessed in the morning after an overnight fast; patients maintained decumbent position for 20 minutes, at a room temperature of 22°C. The imaging of the brachial artery, 2-5 em above the antecubital fossa, was obtained by high resolution ultrasonographic device equipped with a 10 MHz linear-array transducer (Agilent ImagePoint Hx, Agilent Technologies, MA, USA). The left brachial artery was scanned over a longitudinal section, obtaining good quality frames synchronized on the R wave of the ECG. The brachial artery blood flow velocity was measured by means of pulsed-wave Doppler signal, placing the sample volume in the center ofthe artery; peak flow rate echo-Doppler measurements were performed on the brachial artery at rest, during reactive hyperemia and after sublingual nitrate admiriistration. Measurements of the artery internal diameter were taken from the anterior to the posterior wall at the interface between media and intima or to the hardest echo (HM" line), at end diastole; the ultrasound transducer was maintained on the brachial artery by a dedicated stereotactic probe-holding device.
The endothelium-dependent flow-mediated vasodilation (FMD) was assessed by measuring the maximal increase in the internal diameter of the brachial artery during reactive hyperemia evoked by the release of a cuff inflated to 250 mm Hg for five minutes on the upper arm, distal to the measurement site. After cuffdeflation, the maximal peak flow rate was measured at 15" and 30"; the changes in brachial artery diameter were measured every 30" for six minutes and were reported as a percentage of the baseline. Reference normal values for FMD were5 % (16) . Subsequently, after a rest period of 15 minutes, baseline measurements (diameter and flow velocity) of the brachial artery were repeated, and the endotheliumindependent vasodilation (nitrate mediated vasodilation, NMD) was evaluated by sublingual administration of 300 meg of nitro-glycerine spray; subsequently, the diameter of the brachial artery was measured at 30 second intervals for 7 minutes, and changes in brachial artery diameter were reported as percent of basal values. Reference normal values for FMD were~10% (16) .
Endothelial function was evaluated at day 0, at weeks 1, 2 and 6 and subsequently every 6 months from the beginning of the anti-TNF-(l treatment.
Statistical analysis
Data are expressed as mean ± SD if not otherwise stated. Obtained variables were tested for normal distribution by the Kolmogorov-Smimov test. The values obtained in each group and the differences between measurements were analyzed by paired or unpaired Student's t-test or by analysis ofvariance (ANOVA) forrepeated measurements, followed by Bonferroni's test; the Wilcoxon test was used when otherwise appropriate. Linear regression analysis with Pearson correlation coefficient was used to investigate the relationship between variables. The chi-square test was used to compare the proportions of patients responsive to each anti-TNF-(l treatment with patients requiring drug discontinuation. The Kaplan-Mayer method was used to generate estimations of event-free persistent response to each biological agent employed. Results were considered statistically significant if p < 0.05.
RESULTS
Patients showed a baseline FMD significantly lower than controls (4.6 ± 4.1 % vs 13.7 ± 5.3, P < 0.05), which resulted below normal values in 16/24 cases (66.7%), with a normal NMD (13.4 ± 5.27 % vs 17.9 ± 3.45 %, p = ns), thus demonstrating the significant occurrence of ED in our RA patient population, statistically unrelated to years of disease as well as to methotrexate and corticosteroid dosages used before biological drug treatment.
The anti-TNF-(l treatment significantly increased FMD from baseline values of 4.6 ± 4.1% to 11.5 ± 4.8% (p < 0.05) at week 1, to 11.3 ± 4.1% (p < 0.05) at week 2, peaking to 13.5 ± 6.0% at week 6 (p < 0.05) (Fig. 1) .
The functional endothelial improvement occurred rapidly after starting anti-TNF-(l therapy, as reflected by statistically significant improvement of FMD during early anti-TNF -(l treatment «6 months), occurred without significant differences among three biological agents, characterized only by poor changes among the patterns of vascular response, characterized by a progressive improvement of FMD during infliximab and adalimumab, while etanercept induced a more fluctuating and less stable improvement (Fig. 1 ).
Long-time analysis of the FMD response to the treatment showed values of 9.6 ± 4.6% (p <0.05) in 24 pts at month 6, 10.4 ± 4.9 % (p < 0.05) in 24 pts at year 1, 12.3 ± 8.0% (p <0.05) in 18 pts at year 2, 6.1 ± 3.2% (p = ns) in 7 pts at year 3,5.8 ± 2.5% (p = ns) in 5 pts at year 4 and of9.4 ± 6.7 % (p = ns) in 4 pts at year 5 (p < 0.05).
Comparing the clinical and endothelial response after 2 years of anti-TNF-a treatment, we found a different percentage of responder patients in continuous treatment, with 25% for infliximab, 60% for etanercept and 100% for adalimumab (p<O.O 1); all of these exhibit persistent clinical and endothelial response, but FMD showed mean values of8.2 ± 7.2 vs 2.8 ± 2.1, (p = ns) for infliximab, 11.6 ± 9.7 vs 6.1 ± 5.1 (p = ns) for etanercept and 14.8 ± 8.0 vs 3.4 ± Table I . Clinical and laboratory parameters at 6 weeks ofanti-TNF-a treatment.
Baseline
After treatment (mean:l: SD) (mean :I:± SD) P The long-term response among three biological agents is influenced by the high incidence of drop-outs; in fact, the anti-TNF-a treatment was discontinued in three patients treated with etanercept and in five patients treated with infliximab. The adverse effects that prompted the discontinuation of the anti-TNF regimen, were recorded for three women, treated with etanercept, who experienced subcutaneous abscesses or pneumonia, and in a man with hypercholesterolemia, treated with infliximab, who was admitted to ICU for myocardial ischemia complicated by atrial arrhythmias. Each adverse event was associated to an overt FMD decrease, that accompanied or took place before the clinical event, as observed in the last patient, which showed an absent flow-mediated vasodilation.
Further 4 women, treated with infliximab, experienced loss of response, characterized by an increasing articular involvement accompanied by a progressive decrease of FMD, occurring :s 2 years of treatment. Loss of response was counteracted by shifting the biological treatment to adalimumab, producing a restored clinical and endothelial response, persistent after 2 years.
At present, only 1 patient is at 4 years of adalimumab treatment and 4 patients are at 5 years of etanercept treatment.
The clinical and biological RA improvement was accompanied by a significant decrease in the DAS score (from 6.3 ± 1.6 to 5.1 ± 1.38, P < 0.05) and ESR values (from 40.5 ± 24.3 to 24.7 ± 14.8 mm/h, p < 0.05), while CRP, rheumatoid factor, triglyceride, cholesterol, systolic and diastolic blood pressure values showed not significant changes at 6 weeks (Table I) .
DISCUSSION
In our RA patient population, ED was highly prevalent, suggesting that an abnormal vasoreactivity with a reduced FMD characterizes RA, as supported by other studies (17) (18) . Indeed, the impaired FMD in the presence of a normal NMD may be regarded as a marker of vascular impairment, strictly related to systemic inflammation, with a marked impairment in the functional vascular flow reserve, driven by TNF-a and other pro-inflammatory cytokines and counteracted by all TNF-a antagonists, thus confirming the prominent role of TNF-a in RA endothelial dysfunction (10, 19) .
The lower basal values of FMD support the evidence of a poor control of the DMARDs on ED in patients with a long-lasting rheumatoid disease; only the anti-TNF-a biological agents manifest the specific property to reverse ED, with a clear, prompt and sometimes long-lasting endothelial improvement (17) (18) .
We found a striking short-term relationship between FMD and clinical and biological response to the anti-TNF-a treatments; a long-term efficacy, up to 2 years of drug therapy, was recorded only in patients treated with etanercept or adalimumab. In particular, adalimumab normalized the FMD at 2 years of treatment in all patients.
Other biological response modifiers show a different rate of discontinuation: 4 patients initially receiving infliximab experienced loss of efficacy in the late course; another 4 patients, 3 of whom were initially treated with etanercept and 1 with infliximab, discontinued the biological drugs because ofthe appearance of serious infections or myocardial ischemia, near the beginning of the treatment.
Thus, we can hypothesize two types of different events, opposite in origin, because all the side effects that are characterized by systemic or localized infections or by myocardial ischemia, occurred after 2-6 months of therapy and seem to be due to an excess of the TNF-a blockage, perhaps related to marked fluctuations of serum levels of the biological drug related to their pharmacodynamic properties. The slowly decreasing clinical and endothelial response after a long initial response are all later in appearance, usually scattered after 1-2 years of infliximab therapy, resembling the occurrence of a treatment escape, likely related to the induction of antibodies vs the biological agent or to unproven changes in the cytokine network (19) (20) . Remarkably, a worsening FMD was recorded both in patients with infectious or cardiovascular events and in patients with a loss of therapeutic response, thus this vascular marker of ED accompanies or sometimes precedes all these events.
The strict coherence between FMD and clinical response is a particular and relevant finding of our study, as stressed by the occurrence of an early FMD normalization followed by a worsened FMD, in all patients who discontinued the first line biological treatment. Remarkably, the infliximab-treated patients who exhibit a loss of efficacy manifested a restored response after they were moved to adalimumab therapy (18, (21) (22) .
Our findings indirectly demonstrate the key role of TNF-a in causing ED when taking into account the favourable changes obtained with different modalities of TNF-a specific antagonism, irrespective of concurrent conventional DMARD administration and clearly overcoming the small and non-significant changes occurring in traditional cardiovascular risk factors, such as cholesterol, triglyceride serum levels and blood pressure levels, not tapered by concurrent therapy with statins, given according to NCEP guidelines (25) . Furthermore, the finding of a sudden decrease or absence of FMD may be regarded as suggestive of a pathophysiological role of other cytokines, in particular IL1, in the presence of a cytokine network unbalance, concurrent with the TNFa block given by the biological agent (20) (21) (22) (23) .
The relevant issue of whether the effects observed in endothelial function after anti-TNFa administration are mostly due to TNFa blockade per se or to the overall suppression of the inflammatory process is difficult to be addressed. An eventual relationship between TNFa serum concentrations and FMD might favor the first. Indeed, in previous studies, both on rheumatoid arthritis and on ANCAassociated systemic vasculitis, the treatments with anti-TNFa antibodies induced no significant changes in serum TNFa levels, regardless of improved endothelial function, thus suggesting that the tissue levels of cytokines are likely to be mostly important in the disease process. Furthermore, TNFa is considered as driving IL-6 expression, and the favourable changes in the patients treated might arise from the resulting reduction of IL-6 and CRP.
The strict relationships initially found among FMD and CRP or ESR levels were lost after 6 weeks, suggesting that anti-TNF-a drugs disrupted the coherence between inflammation and systemic disease activity, as measured by DAS28 score. -
The pivotal role played by TNF-a in RA endothelial dysfunction is further supported by our data showing the basal FMD impairment in most patients treated with usual DMARDs and corticosteroids, that per se seem to have little effect on RA cardiovascular changes and reduced life expectation (24) (25) (26) (27) .
Clinical and experimental studies lend support to the view that anti-TNF-a treatment may selectively counteract ED related to a systemic inflammation, through several mechanisms increasing the nitric oxide biodisponibility, restoring the balance between endothelial and inducible nitric oxide synthase activity, with a down-regulated expression of the vascular inducible nitric oxide synthase (17) .
Our findings showed an early and often persistent reversibility of endothelial dysfunction, thus suggesting that endothelial dysfunction is a relevant feature of the rheumatoid disease process, driven by TNF-a. ED could therefore be regarded as a sensitive biomarker of subclinical or overt cardiovascular involvement in RA, because a poor endothelial function is induced by the same mechanisms of rheumatoid inflammation, may be efficaciously reverted by currently available biological disease modifiers and is probably predictive for an increased rate of subsequent cardiovascular events such as asymptomatic or overt cardiovascular involvement (24) (25) (28) (29) .
The long-term improvement of endothelial dysfunction in RA patients induced by adalimumab further supports data indicating that this biological drug is effective and well-tolerated in RA patients even if previously treated with other TNF-a blocker drugs (29) .
The present data further support that a maintained coherence between endothelial and synovial responses could be employed to integrate actual response criteria to optimize the current therapeutic strategy. The FMD should be regarded as a useful non-invasive and inexpensive biological marker of vascular involvement in rheumatoid disease, indicative of its inflammatory burden, in order to obtain a persistent disease remission with reduced risks of systemic or cardiovascular events (30) .
